附近上门

Precision medicine company closed a $2.5 million seed round of funding to develop personalized birth control.

Subscribe to the 附近上门 Daily

The seed round, the Seattle-based company鈥檚 first institutional funding, was co-led by and with participation from , and , as well as a group of angel investors including , , and .

Medication side effects are the main reason women switch birth control methods, adyn founder told 附近上门 News. Those side effects can range from acne and weight gain to major risks, such as blood clots and depression. Each year in the U.S., among every 10,000 women, 5 to 10 women will experience a blood clot, according to a .

adyn鈥檚 first product, the Birth Control Optimization Test, is an at-home kit enabling users to collect both saliva and finger prick samples to measure hormone baseline levels and aims to assess genetic risk for blood clots and depression.

The company鈥檚 technology then synthesizes a medical biography with side effect profiles of estrogens and progestins used in hormonal contraception. A physician approves the prescription and the results. adyn is also building in a telemedicine visit so that women can receive assistance in understanding the results.

Removing trial-and-error

As a Ph.D. in genetics and genomics, Ruzzo spent more than 10 years researching and identifying genetic risk for complex diseases such as epilepsy and autism, and in precision medicine. During her research, she found that the average woman in the U.S. takes birth control for 30 years, but the standard of care for hormonal birth control prescription is still trial and error, with the average time spent on contraceptive counseling being 12.9 minutes.

鈥淯ntil now, there was no intelligent way to pick between the 200 options available in the U.S.,鈥� said Ruzzo, who founded adyn in 2019. 鈥淲e are bringing science into this to take away the trial and error.鈥�

Like many women, Ruzzo went on birth control at an early age as a method to treat acne. At the same time, she was also taking a prescription acne medication known to cause depression, she said.

When she began experiencing the depression symptoms, she figured it was caused by the acne medication. Later, when she was only on the birth control, the symptoms began to get worse, to the point that Ruzzo said she considered suicide.

鈥淚 spoke with my medical professional, who said no, it couldn鈥檛 be the birth control, but when I went off of it, I began to feel better,鈥� she added. 鈥淚 wondered why I was essentially 鈥榤edically gaslighted,鈥� and why my doctor didn鈥檛 help me. I certainly didn鈥檛 know there were that many birth control choices.鈥�

Next steps

Ruzzo intends to use the funding to grow her team and launch the waiting list for the optimization test to get it in the hands of users.

In addition to birth control, adyn is considering other hormonal use cases, including menopause, as well as leveraging data to understand if a diagnosis of PCOS (polycystic ovary syndrome) or endometriosis could be made with less invasive diagnostic methods.

Meanwhile, Lux Capital Partner said in a statement that adyn is offering better options for women related to family planning and control over their health.

鈥淒r. Ruzzo and her team have achieved a breakthrough in both technology and business model, which together will fundamentally transform the quality and precision of health care diagnostics and delivery,鈥� Shakir added.

In addition, M13 Partner and Head of Brand said in a statement that adyn is introducing 鈥渁 new standard of care for birth control and closing gaps caused by historic inequity in medical research.鈥�

Next up, Ruzzo intends to navigate the women who have pre-ordered the optimization test through the full experience and then will bring people off of the waiting list.

鈥淧eople have found adyn without us doing any marketing, which is a testament to how needed it is,鈥� she added. 鈥淚t is an incredible motivator to hear people鈥檚 stories, how hard it was to find the right birth control and how positive it was when they did.鈥�

Illustration: